Sylatron FDA Approval History
FDA Approved: Yes (First approved March 29, 2011)
Brand name: Sylatron
Generic name: peginterferon alfa-2b
Company: Merck
Treatment for: Melanoma
Sylatron (peginterferon alfa-2b) is an alpha interferon indicated for the adjuvant treatment of melanoma.
Development timeline for Sylatron
| Date | Article |
|---|---|
| Apr 12, 2011 | Approval FDA Approves Merck's Sylatron (peginterferon alfa-2b) for Injection, a New Adjuvant Treatment for Melanoma with Microscopic or Gross Nodal Involvement |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
